Pharvaris N.V. (PHVS) Research

Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.

Market snapshot

Symbol
PHVS
Price
$32.80
Day change
-1.83%
Market cap
$2.0B
P/E ratio
-11.04x
52-week range
16.72-34.41
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$56.00

Peer companies

  • Ardelyx, Inc. (ARDX)
  • BioCryst Pharmaceuticals, Inc. (BCRX)
  • Immunome, Inc. (IMNM)
  • Maze Therapeutics, Inc. (MAZE)
  • Intellia Therapeutics, Inc. (NTLA)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Spyre Therapeutics, Inc. (SYRE)
  • Upstream Bio, Inc. (UPB)

Recent insider activity

  • Modig Berndt — S-Sale (2191 shares) on 2026-06-15
  • Modig Berndt — S-Sale (100 shares) on 2026-06-15
  • Lu Peng — F-InKind (117 shares) on 2026-06-12
  • Lu Peng — F-InKind (109 shares) on 2026-06-11
  • Nijdam Anna — S-Sale (2670 shares) on 2026-06-04

Open Pharvaris N.V. (PHVS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.